Zoetis (NYSE:ZTS) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on March 3rd. The trade occurred in the Representative's "MERRILL LYNCH LONG TERM GROWTH" account.

Representative Julie Johnson also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Capital One Financial NYSE: COF on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 3/19/2025.
• Purchased $1,001 - $15,000 in shares of The Cigna Group NYSE: CI on 3/19/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 3/14/2025.
• Sold $1,001 - $15,000 in shares of Accenture NYSE: ACN on 3/12/2025.
• Purchased $1,001 - $15,000 in shares of 3M NYSE: MMM on 3/12/2025.
• Sold $1,001 - $15,000 in shares of Webster Financial NYSE: WBS on 3/11/2025.
• Sold $1,001 - $15,000 in shares of Sonos NASDAQ: SONO on 3/11/2025.
• Sold $1,001 - $15,000 in shares of Taiwan Semiconductor Manufacturing NYSE: TSM on 3/11/2025.
• Sold $1,001 - $15,000 in shares of Teradyne NASDAQ: TER on 3/3/2025.

Zoetis Stock Up 2.2 %

NYSE:ZTS traded up $3.26 during trading hours on Tuesday, reaching $150.11. The company had a trading volume of 881,193 shares, compared to its average volume of 2,531,707. The business's 50-day simple moving average is $159.49 and its two-hundred day simple moving average is $169.35. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market cap of $66.97 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.78 and a beta of 0.92. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.33%. Zoetis's payout ratio is presently 36.56%.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent research reports. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $214.40.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Zoetis during the 4th quarter valued at $824,321,000. Wellington Management Group LLP raised its position in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares in the last quarter. Sarasin & Partners LLP bought a new stake in Zoetis during the first quarter worth about $339,111,000. GAMMA Investing LLC boosted its holdings in shares of Zoetis by 14,731.3% in the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Zoetis during the 4th quarter valued at about $196,651,000. 92.80% of the stock is currently owned by institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024. Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.